Physician profile
Mariam Hasan
NPI 1851604847
$2,534.80
in general payments reported to CMS, 2019-2025
19 companies · $306 in 2025
The $306 reported for 2025 was more than what 84% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.55 · 2020: $39.70 · 2021: $428 · 2022: $150 · 2023: $1,036 · 2024: $537 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $963 · Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $962.50 |
| Food and Beverage | $916.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $962.50 | 2023 | |
| Merz North America, INC. | $487.13 | 2021-2022 | |
| Lilly USA, LLC | $335.94 | 2020-2025 | Mounjaro, Zepbound |
| Almatica Pharma LLC | $124.12 | 2024-2025 | Loreev Xr |
| Phathom Pharmaceuticals, INC. | $103.88 | 2024 | Voquezna |
| Novo Nordisk INC | $102.63 | 2021-2024 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $67.79 | 2024 | |
| Abbvie INC. | $46.73 | 2025 | |
| Amgen INC. | $41.96 | 2025 | Repatha |
| Otsuka America Pharmaceutical, INC. | $40.49 | 2024-2025 | Rexulti |
| Portola Pharmaceuticals, LLC | $38.55 | 2019 | |
| Mylan Specialty L.P. | $32.57 | 2023 | Yupelri |
| Eisai INC. | $30.83 | 2021 | |
| Cipher Pharmaceuticals US LLC | $25.30 | 2025 | Spinosad, Natroba |
| Lucid Diagnostics INC. | $19.62 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.57 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.01 | 2025 | Cobenfy |
| Kowa Pharmaceuticals America, INC. | $18.60 | 2024 | Zoryve |
| Merck Sharp & Dohme LLC | $17.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.